Biodesix(US:BDSX)2026-02-26 21:06Financial Performance - Total revenue for Q4 was $28.8 million, up 41% year-over-year, with a full-year revenue of $88.5 million, reflecting a 24% increase [505]. - Diagnostic Tests core organic revenue reached $24.1 million in Q4, a 40% increase year-over-year, driven by a 23% growth in test volume [491]. - Development Services revenue increased to $3.6 million in Q4 and $9.3 million for fiscal 2025, marking a 12% and 41% growth respectively [491]. - Gross margin expanded by 400 basis points to 83% in Q4 and by 300 basis points to 81% for the full year, attributed to improved average revenue per test and optimized workflows [491]. - Net loss improved to $4.0 million in Q4 and $35.3 million for fiscal 2025, representing a 52% and 18% improvement year-over-year [491]. Research and Development - Biodesix plans to increase investment in research and development to support the innovation of new products and clinical studies, with a focus on economic impact and payer coverage [484]. - The company completed enrollment of 5,000 patients in the ongoing INSIGHT study, aimed at expanding the clinical understanding of the VeriStrat test, with follow-up expected to conclude by the end of 2026 [484]. - Research and development expenses rose by $2.4 million or 26% for the year ended December 31, 2025, primarily due to increased employee compensation and clinical trial costs [510]. - Total research and development expenses increased by $2.4 million or 26% in 2025, reaching $12.0 million compared to $9.6 million in 2024 [511]. Sales and Marketing - The company is expanding its field sales force and customer support teams to enhance product education and sales efforts in clinical settings [488]. - The company anticipates increased sales and marketing expenses to attract new biopharmaceutical customers and maintain existing relationships, aiming for growth in Development Services [488]. - Sales, marketing, general and administrative expenses rose by $7.1 million or 9% in 2025, primarily due to increased employee compensation and benefits to support sales growth [511]. Operational Highlights - Biodesix's Development Services have been utilized by over 65 industry clients and academic partners, contributing to the company's revenue growth and expanding its knowledge in multiple diseases [477][480]. - The ALTITUDE study, launched in Q4 2020, reached patient enrollment requirements in July 2025, focusing on demonstrating the utility of the Nodify CDT and XL2 tests [485]. - The company has achieved over 90 peer-reviewed publications for its tests, enhancing its credibility and supporting physician adoption [487]. - All five blood-based lung diagnostic tests are covered by Medicare, which is crucial for revenue generation and reimbursement stability [482]. Financial Position and Cash Flow - Cash and cash equivalents stood at $19.0 million as of December 31, 2025, including $2.3 million from at-the-market proceeds, with an additional $14.7 million raised post-quarter [491]. - Net cash used in operating activities was $23.3 million in 2025, a decrease of approximately $25.4 million compared to $48.6 million in 2024, mainly due to favorable changes in net working capital [526]. - Net cash provided by financing activities totaled $16.4 million in 2025, a decrease of $35.6 million compared to $52.1 million in 2024, driven by proceeds from the issuance of Tranche C and common stock [528]. - The company recorded other income of $0.6 million in 2025, up from $0.1 million in 2024, primarily related to interest and other income [516]. - The company had a net decrease in cash and cash equivalents of $7.3 million in 2025, compared to a net decrease of $39,000 in 2024 [526]. Debt and Obligations - The company amended its Senior Secured Term Loan to extend the maturity date to November 2028, enhancing financial flexibility [491]. - As of December 31, 2025, the Company had $50.0 million outstanding on the Perceptive Term Loan Facility, with an annual interest rate of at least 3.0% plus a margin of 9.0% [539]. - The company has non-cancelable contractual obligations and commitments totaling $105.8 million as of December 31, 2025 [529]. - Interest expense decreased by $0.5 million or 7% in 2025, primarily related to the Perceptive Term Loan Facility [512]. Market Risks - The Company is classified as a "smaller reporting company," allowing it to provide reduced disclosure obligations until certain revenue and market value thresholds are met [537]. - The Company is exposed to market risk due to potential adverse changes in financial market prices and rates, impacting its financial position [538]. - A hypothetical 100 basis point increase in interest rates would have an estimated $0.5 million annual impact on the Company's financial position based on the current Perceptive Term Loan [541]. Revenue Recognition - The Company recognizes revenues from blood-based lung diagnostic billings based on estimates of expected collections, considering factors like test type and payment history [533]. - Revenue for patients without contracts is recognized when contracts are established or when the Company receives substantially all consideration after performance obligations are met [534]. - Development Services revenue is accrued upon completion of performance obligations, typically involving large biopharmaceutical companies, with contracts generally expected to be completed in one year or less [535].